South Africa’s new HIV prevention injection, lenacapavir, provides protection for six months with a single dose, removing the need for daily medication. Almost 55,000 individuals in the country have already received it, according to the health department.
The injection, also known as LEN, has been available through government clinics since June. It offers near-perfect protection against HIV and requires only two clinic visits annually. Currently, 360 clinics across six provinces provide LEN, but this is expected to expand as more affordable generic versions become available in 2027. The provinces of the Free State, Limpopo, and the Northern Cape are yet to receive the injection, highlighting the need for broader distribution.
Transforming Prevention for High-Risk Groups
The health department targets high-risk groups, including teenage girls, sex workers, transgender women, and gay and bisexual men. These groups face a higher risk of contracting HIV due to various socio-economic and behavioral factors. LEN provides a convenient and effective prevention method, addressing the specific needs of these populations. Additionally, pregnant and breastfeeding women are also prioritized, as they require safe and reliable HIV prevention options.
Individuals can choose between a daily prevention pill and the six-monthly injection, both offered free of charge. The injection process involves two initial shots, administered in the abdomen or buttocks, along with four tablets taken over two days. Subsequent injections, given 24 to 28 weeks later, do not require additional tablets. This regimen simplifies adherence, a critical factor in effective HIV prevention.
Personal Stories: Why They Chose LEN
Precious Mafanga, a 39-year-old sex worker and peer educator, switched from the daily pill to LEN. She emphasizes the challenges of her work, where time is money, and the pressure to engage in unsafe sex for higher pay. LEN’s six-month protection eliminates daily reminders, making it a practical choice for her lifestyle. Mafanga also highlights the importance of condom use, as LEN does not protect against other sexually transmitted infections or pregnancy.
Siviwe Gaika, a 24-year-old law student, faced barriers before receiving her LEN injection. She had to visit the clinic three times and wait four hours during one visit. Gaika values the convenience of LEN, as her busy schedule made daily pill-taking impractical.
Read Also: What Is Health Care Management and Why It Is Essential for Modern Healthcare Systems
Dimpho Tsotetsi, a 32-year-old trans woman and peer educator, chose LEN after years of struggling with pill fatigue. The injection’s discreet nature is particularly beneficial for the trans community, where taking HIV prevention medication can be stigmatized. Despite initial discomfort from the bumps, Tsotetsi finds LEN to be a simpler and more sustainable option.
Expanding Access for Greater Impact
While LEN shows promise, South Africa must scale up its distribution to significantly impact HIV prevention. Modeling suggests that one to two million people would need to use LEN annually by 2043 to help end AIDS as a public health threat. The health department’s plans to expand access, coupled with the introduction of generic versions, are essential steps toward this goal. Funding from the Children’s Investment Fund Foundation through the Global Fund will play a key role in this expansion.
The experiences of Mafanga, Gaika, and Tsotetsi highlight the potential impact of LEN. By addressing the practical challenges of daily pill-taking, the injection offers a more reliable and convenient option for those at highest risk. As access expands, LEN could significantly contribute to South Africa’s fight against HIV, offering hope for a future where prevention is both effective and accessible.